Glaxo: ViiV Healthcare Reports Positive HIV Trial Results

GlaxoSmithKline joint-venture company ViiV Healthcare said Thursday that a global phase 3 “Atlas-2M” study of rilpivirine for the treatment of HIV met its primary endpoint.

ViiV Healthcare–which is jointly owned by Pfizer–said the study showed a combination of cabotegravir and rilpivirine administered every eight weeks is similar to a four-week administration.

“The Atlas-2M study results mean that people living with HIV could maintain viral suppression with six total treatments per year, instead of a daily oral treatment 365 times per year,” Viiv Healthcare’s Head of Research & Development Kimberly Smith said.

https://www.marketscreener.com/GLAXOSMITHKLINE-9590199/news/GlaxoSmithKline-ViiV-Healthcare-Reports-Positive-HIV-Trial-Results-29099379/